CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. These results were presented at the 7th International Conference on Complement Therapeutics being held June 6 – 11, 2014, in Olympia, Greece.
Help employers find you! Check out all the jobs and post your resume.
